NOPE37: Angiogenic Factors for Managing Term Preeclampsia

Condition(s) studied

Investigational drug(s) / intervention(s)

Intervention arm: expectant management if sFlt-1/PlGF<38: If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.

Standard care: elective delivery at 37 weeks of gestation: In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.

Study summary

This study tests the hypothesis that, in women with preeclampsia without severe features, delivery management based on sFlt-1/PlGF would reduce the rate of induction of labor without worsening the rate of progression to preeclampsia with severe features and other maternal complications.

Eligibility

Primary outcome measure(s)

• Composite maternal outcome — through study completion, an average of 2 months
  The primary outcome is a composite poor maternal outcome, defined as maternal mortality, severe maternal morbidity (eclampsia, HELLP syndrome, thromboembolic disease, pulmonary edema, or placental abruption), preeclampsia with severe features, and major postpartum hemorrhage (\>1000 mL).

Trial sites (23)

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Other trials for the same condition